

Proanthocyanidins from *Spenceria ramalana* and Their Effects on AGE Formation in Vitro and Hyaloid-Retinal Vessel Dilation in Larval Zebrafish in Vivo

Ik-Soo Lee,^{†,||} Song Yi Yu,^{†,||} Seung-Hyun Jung,[†] Yu-Ri Lee,[†] Yun Mi Lee,[†] Joo-Hwan Kim,[‡] Hang Sun,[§] and Jin Sook Kim^{*,†}


[†]KM-Based Herbal Drug Research Group, Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305–811, Republic of Korea

[‡]Department of Life Science, Gachon University, Seongnam, Gyeonggi-do 461-701, Republic of Korea

[§]Laboratory of Biodiversity and Biogeography, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650204, People's Republic of China

Supporting Information

ABSTRACT: Three new A-type proanthocyanidins (1–3), *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-afzelechin 3'-O- β -D-glycopyranoside (1), *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-afzelechin (2), and *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-epicatechin-(2 α →O→7,4 α →8)-*ent*-afzelechin (3), and three known compounds (4–6) were isolated from the whole plant of *Spenceria ramalana*. The structures of the new proanthocyanidins were established by spectroscopic and chemical studies. The inhibitory effects of compounds 1–6 on the formation of advanced glycation end products were examined in vitro. Compounds 3 and 6 showed the strongest inhibition, with IC₅₀ values of 17.4 ± 0.5 and 14.1 ± 1.6 μ M, respectively. The effects of these isolates on the dilation of hyaloid-retinal vessels induced by high glucose (HG) in larval zebrafish were also investigated. Compound 3 reduced the dilation of HG-induced hyaloid-retinal vessels most effectively. This compound reduced the diameters of HG-induced hyaloid-retinal vessels by about 157.7% and 164.1% at 10 and 20 μ M, respectively, versus the HG-treated control group.




Diabetic vascular complications are leading causes of end-stage renal failure, acquired blindness, various neuropathies, and accelerated atherosclerosis. Chronic hyperglycemia plays a major role in the initiation of diabetic vascular complications through various hyperglycemia-induced metabolic and hemodynamic derangements, including increased advanced glycation end-product (AGE) formation, increases in the polyol pathway, activation of protein kinase C isomers, and increases in the hexosamine pathway.^{1–4} Of these factors implicated in the pathogenesis of diabetic vascular complications, enhanced formation and accumulation of AGE, heterogeneous molecules derived from nonenzymatic glycation between amino acid residues and oxidative derivatives of glucose or pentose, is irreversible, causing structural and functional changes in proteins, such as collagen, elastin, and albumin, leading to the development of diabetic vascular complications, including diabetic retinopathy, neuropathy, and nephropathy.⁵ Because of the potential role of AGE in diabetic vascular complications, the development of pharmacological compounds that inhibit the formation of these glycosylated products may provide a therapeutic approach for delaying and preventing diabetic vascular complications.

Spenceria ramalana Trimen, a species in the genus *Spenceria*, belonging to the family Rosaceae, is a perennial herb, native to China, distributed in a large cross-section of Shanyu Tibet, Yunnan, and Sichuan. It has been used in traditional folk medicine in China for the treatment of various ailments, including lumbago, stomachache, and dysentery.⁶ To date, there has been no study of the chemical constituents or biological activities of this plant. In searching for new AGE inhibitors from natural sources, we found that the EtOAc-soluble fraction of the 80% EtOH extract of the whole plant of *S. ramalana* had a considerable inhibitory effect on AGE formation (IC₅₀ = 19.92 ± 0.13 μ g/mL). Further phytochemical study of this fraction resulted in the isolation of three new (1–3) and three known dimeric A-type proanthocyanidins (4–6). In this report, we describe the isolation and structural elucidation of these compounds, as well as the characterization of their inhibitory effects on AGE formation. The effects of these isolates on the dilation of high-glucose (HG)-induced hyaloid-retinal vessels in larval zebrafish were also investigated.

Received: June 4, 2013

Published: October 16, 2013



RESULTS AND DISCUSSION

An 80% (v/v) EtOH extract of the whole *S. ramalana* plant was suspended in H₂O and successively partitioned using *n*-hexane, EtOAc, and *n*-BuOH. The EtOAc-soluble fraction was subjected to a series of chromatographic steps, resulting in the isolation of six proanthocyanidins (1–6). Of these, three were identified as *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-afzelechin (4),⁷ *ent*-epiafzelechin-(2 α →O→7,4 α →8)-afzelechin (5),⁸ and *ent*-epiafzelechin-(2 α →O→7,4 α →8)-catechin (6),⁹ by comparison of observed and published physicochemical data.

Compound 1 was obtained as a white powder, with the molecular formula C₃₆H₃₄O₁₅, as established by HRESIMS, based on the [M + H]⁺ peak (*m/z* 707.1970). The IR spectrum exhibited absorption bands for hydroxy (3450 cm⁻¹) and aromatic (1610 and 1520 cm⁻¹) functional groups. A positive vanillin–sulfuric acid test and a UV absorption maxima observed at 272 nm suggested the presence of a flavan structure in 1.¹⁰ The ¹H NMR spectrum (Table 1) of 1 exhibited characteristic peaks for two *meta*-coupled doublets [δ_{H} 6.07 and 5.96 (each d, *J* = 2.2 Hz)], an aromatic singlet (δ_{H}

6.09), and two pairs of A₂B₂ aromatic system protons [δ_{H} 7.51 and 6.83 (each d, *J* = 9.0 Hz) and δ_{H} 7.34 and 6.84 (each d, *J* = 8.4 Hz)]. Additionally, an isolated AB system [δ_{H} 4.15 and 4.31 (each d, *J* = 3.6 Hz)] in the heterocyclic proton region was observed, characteristic of the C-ring protons of A-type proanthocyanidins, consisting of two flavanyl units.¹¹ Such a structural type was supported by the typical acetal carbon resonance at δ_{C} 100.7 in the ¹³C NMR spectrum (Table 1). The interflavonoid linkage between the two flavanyl units was established by methylation of 1 with diazomethane, yielding pentamethyl ether (1a). The ¹H NMR spectrum of 1a exhibited, together with four methoxy signals at δ_{H} 3.72–3.82, one upfield methoxy signal at δ_{H} 3.31 assignable to MeO-5 due to the anisotropic shielding of the E-ring in the lower flavanyl unit.^{12,13} This suggests that the two flavanyl units were linked through the C-4 and C-8' positions. The existence of a (2→O→7') rather than a (2→O→5') ether linkage was deduced from the NOE correlation between a methoxy signal at δ_{H} 3.75 (3H, s, MeO-5') and H-4' methylene signals (δ_{H} 2.72–2.92, F-ring) in 1a. The (4→8', 2→O→7') interflavonoid linkage of 1 was further supported by observation of the HMBC cross-peaks of H-3 with C-8' and of H-4 with C-7', C-8', and C-9' (Figure 1). The absolute configuration at C-4 on the heterocyclic C-ring was determined from the sign of the Cotton effect in the region 220–240 nm.¹⁴ A negative Cotton effect around 230 nm ([Θ]₂₃₂ –9230) in the electronic circular dichroism (ECD) spectrum of 1 leads to assignment of a 4*S*-configuration of the C-ring, thus confirming the (2 α ,4 α)-configuration of the C-ring because the linkage of the two units of A-type proanthocyanidins must be *cis*.¹⁵ The NOESY cross-peak between H-3 (δ_{H} 4.15, C-ring) and H-6' (δ_{H} 5.96, D-ring) indicated the 3,4-*trans* configuration of the C-ring (Figure 2). On the basis of these data, the absolute configuration of the C-ring was deduced to be 2*R*,3*S*,4*S*, and thus the upper flavanyl unit of 1 was identified as *ent*-epiafzelechin. The absolute configuration at C-2' of the F-ring was established from the ECD spectrum. Flavan-3-ols with 2*R* and 2*S* absolute configuration give rise to negative and positive Cotton effects, respectively, in the 260–280 nm region of their ECD spectra.¹⁶ Thus, the weak positive Cotton effect around 270 nm ([Θ]₂₇₁ +580) observed in 1 indicated that the absolute configuration at C-2 of the F-ring differed from that of the C-ring, indicating a 2*S*-configuration of the F-ring.^{7,15} The large coupling constant (*J* = 8.0 Hz) between H-2' and H-3' of the F-ring reflected a relative *trans*-configuration.¹⁷ Consequently, the absolute configurations at C-2 and C-3 of the F-ring were deduced to be *S* and *R*, respectively, and the lower flavanyl unit of 1 was thus identified as *ent*-afzelechin. The carbon signals at δ_{C} 103.9, 78.2, 77.8, 75.4, 71.7, and 62.9 and an anomeric proton signal at δ_{H} 4.12 in 1 were typical of a glucopyranosyl unit. Acid hydrolysis of 1 yielded 4 as the aglycone and a monosaccharide unit identified as D-glucose upon GC analysis. When the ¹³C NMR spectrum of 1 was compared with that of 4, a downfield shift was observed for C-3' of the F-ring by about 7 ppm, indicating the linkage position of a glucopyranosyl moiety at C-3' of the lower flavanyl unit, further supported by the HMBC cross-peak between the anomeric proton (δ_{H} 4.12) and the aglycone carbon (δ_{C} 75.3) for C-3 of the F-ring (Figure 1). Moreover, the large coupling constant (*J* = 7.5 Hz) of the anomeric proton indicated that the glucopyranosyl unit was linked in a β -configuration. Thus, the structure of 1 was determined as *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-afzelechin 3'-O- β -D-glycopyranoside.

Table 1. NMR Data for Compounds 1–3 in Methanol-*d*₄ (500 MHz for ¹H NMR, 125 MHz for ¹³C NMR)

C(ring)	1		2		3	
	δ_{H} (J in Hz)	δ_{C}	δ_{H} (J in Hz)	δ_{C}	δ_{H} (J in Hz)	δ_{C}
2(C)		100.7		101.5		101.5
3(C)	4.15 d (3.6)	67.8	4.28 d (3.5)	67.3	4.28 d (3.5)	68.2
4(C)	4.31 d (3.6)	29.4	4.37 d (3.5)	29.8	4.38 d (3.5)	29.8
5(A)		156.8		157.0		156.9
6(A)	5.96 d (2.2)	98.3	5.92 d (2.2)	98.6	5.93 d (2.2)	98.6
7(A)		158.4		158.5		158.5
8(A)	6.07 d (2.2)	96.8	6.04 d (2.2)	96.8	6.04 d (2.2)	96.8
9(A)		154.3		154.2		154.2
10(A)		104.2		103.6		103.6
11(B)		131.8		131.0		131.0
12(B)	7.51 d (9.0)	129.7	7.67 d (9.0)	129.7	7.67 d (9.0)	129.7
13(B)	6.83 d (9.0)	115.7	6.90 d (9.0)	116.0	6.91 d (9.0)	116.0
14(B)		159.1		159.5		159.5
15(B)	6.83 d (9.0)	115.7	6.90 d (9.0)	116.0	6.91 d (9.0)	116.0
16(B)	7.51 d (9.0)	129.7	7.67 d (9.0)	129.7	7.67 d (9.0)	129.7
2'(F)	5.15 d (8.0)	81.4		100.8		100.8
3'(F)	4.38 ddd (5.6, 8.0, 8.8)	75.3	4.18 d (3.5)	67.6	4.18 d (3.5)	67.6
4'(F)	ax: ^a 2.78 dd (8.8, 16.4) eq: ^b 2.87 dd (5.6, 16.4)	26.9	4.36 d (3.5)	29.6	4.36 d (3.5)	29.6
5'(D)		156.2		158.5		158.4
6'(D)	6.09 s	96.9	6.11 s	96.9	6.11 s	96.9
7'(D)		152.5		154.0		154.0
8'(D)		106.8		108.7		108.6
9'(D)		150.6		147.1		147.1
10'(D)		102.9		103.4		103.5
11'(E)		130.4		131.6		131.6
12'(E)	7.34 d (8.5)	129.5	7.52 d (9.0)	129.7	6.95 d (2.1)	115.5
13'(E)	6.84 d (8.5)	116.6	6.84 d (9.0)	115.7		146.9
14'(E)		159.0		159.2		146.6
15'(E)	6.84 d (8.5)	116.6	6.84 d (9.0)	115.7	6.83 d (6.8)	116.5
16'(E)	7.34 d (8.5)	129.5	7.52 d (9.0)	129.7	6.84 dd (2.1, 6.8)	120.3
2''(I)			4.78 d (8.0)	84.0	4.78 d (8.0)	83.9
3''(I)			4.12 ddd (5.5, 8.0, 9.0)	68.3	4.12 ddd (5.5, 8.0, 9.0)	67.3
4''(I)			eq: 2.60 dd (9.0, 16.5) ax: 3.06 dd (5.5, 16.5)	29.5	eq: 2.60 dd (9.0, 16.5) ax: 3.06 dd (5.5, 16.5)	29.5
5''(G)				157.1		157.0
6''(G)			5.91 s	98.6	5.91 s	98.6
7''(G)				150.2		150.2
8''(G)				108.5		108.5
9''(G)				149.8		149.6
10''(G)				103.9		103.7
11''(H)				130.3		131.0
12''(H)			7.35 d (8.5)	130.1	7.52 d (8.5)	129.7
13''(H)			6.86 d (8.5)	116.5	6.84 d (8.5)	115.7
14''(H)				159.1		159.2
15''(H)			6.86 d (8.5)	116.5	6.84 d (8.5)	115.7
16''(H)			7.35 d (8.5)	130.1	7.52 d (8.5)	129.7
Glc-1	4.12 d (7.5)	103.9				
Glc-2	3.10	75.4				
Glc-3	3.18	78.2				
Glc-4	3.22	71.7				
Glc-5	3.23	77.8				
Glc-6	3.86, 3.64	62.9				

^aAxial proton. ^bEquatorial proton.

Compound **2** was obtained as a white powder and gave a positive result in the vanillin–sulfuric acid test. Its molecular formula, C₄₅H₃₄O₁₅, was determined on the basis of its [M–H][–] peak (*m/z* 813.1826) in the HRESIMS and NMR data,

suggesting the presence of a triflavonoid structure. The ¹H NMR spectrum (Table 1) was similar to those of **4** and **5**, except that **2** had additional signals consistent with the presence of a flavanyl unit [δ_{H} 7.35 and 6.86 (each d, *J* = 8.5




Figure 1. Key HMBC (H→C) correlations of compounds 1–3.




Figure 2. Key NOE (H↔H) correlations of compounds 1–3.

Hz) and 5.91 (s) in the aromatic region; δ_{H} 4.78 (d, $J = 8.0$ Hz), 4.12 (ddd, $J = 5.5, 8.0, 9.0$ Hz), 3.06 (dd, $J = 5.5, 16.5$ Hz), and 2.60 (dd, $J = 9.0, 16.5$ Hz) in the heterocyclic region], suggesting that **2** is a trimeric A-type proanthocyanidin.¹⁸ The two doubly linked units were also demonstrated by the typical acetal carbon resonances at δ_{C} 101.5 and 100.8 in the ¹³C NMR spectrum (Table 1). The methylation of **2** with diazomethane yielded heptamethyl ether (**2a**). The ¹H NMR spectrum of **2a** exhibited two upfield methoxy signals (δ_{H} 3.33 and 3.40), assignable to the methoxy groups at C-5 (A-ring) and C-5' (D-ring), together with five methoxy signals at δ_{H} 3.70–3.83. The unusual upfield shifts of the two methoxy groups indicated the presence of a through-space interaction with the E- and H-rings,^{12,13} suggesting that the two interflavonoid C–C linkages were (4→8') and (4'→8''). The NOESY cross-peaks between a methoxy signal at δ_{H} 3.40 (3H, s, MeO-5') and H-4' (δ_{H} 4.30, F-ring) and between a methoxy signal at δ_{H} 3.70 (3H, s, MeO-5'') and H-4'' (δ_{H} 2.58–3.10, I-ring) of **2a** indicated the presence of (2→O→7') and (2'→O→7'') ether linkages. The unsubstituted phloroglucinol A-ring carbons C-6 (δ_{C} 98.6) and C-8 (δ_{C} 96.8), C-6 (δ_{C} 96.9) of the D-ring, and C-6 (δ_{C} 98.6) of the G-ring in **2**, being similar to those of geraniin D isolated from *Geranium niveum*,¹⁹ further supported that the interflavonoid linkage between the three flavanyl units was (4→8, 2→O→7') and (4'→8'', 2'→O→7''). Although the ¹H and ¹³C NMR spectra of **2** were found to be identical to those of geraniin D, **2** showed a Cotton effect with opposite sign around 240 nm ($[\Theta]_{240} -5820$) relative to that of geraniin D ($[\Theta]_{236} +7760$), indicating that the C- and F-rings had 4*S*-configurations in **2**. The absolute configurations at C-2 of the C-ring and C-2' of the F-ring were thus automatically assigned as *R* and *S*, respectively. Furthermore, the NOESY cross-peaks

between H-3 (δ_{H} 4.15, C-ring) and H-6' (δ_{H} 6.11, D-ring) and between H-3' (δ_{H} 4.15, F-ring) and H-6'' (δ_{H} 5.91, G-ring) indicated the 3,4-*trans* configurations of the C- and F-rings (Figure 2). Thus, both the upper and middle flavanyl units of **2** were identified as *ent*-epiafzelechin. The absolute configuration at C-2''' of the I-ring was determined from the sign of the Cotton effect observed in the 260–280 nm region of the ECD spectrum of **2**. Compared to **1**, the sign of the Cotton effect around 270 nm was identical, but the amplitude in **2** ($[\Theta]_{271} +820$) was larger than that in **1**, $[\Theta]_{271} +580$. This indicates a 2*S*-configuration of the I-ring of **2** because the absolute configurations at C-2 of the C-ring and C-2' of the F-ring of **2** are identical to those of **1**. Because H-2'' and H-3'' of the I-ring were *trans*-oriented ($J_{2,3} = 8.0$ Hz), the lower flavanyl unit was characterized as *ent*-afzelechin. Thus, the structure of **2** was determined to be *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-epiafzelechin-(2 α →O→7,4 α →8)]-*ent*-afzelechin.

Compound **3** gave a positive result in the vanillin–sulfuric acid test and showed a molecular formula of C₄₅H₃₄O₁₆, from its $[M - H]^-$ peak (m/z 829.1771) in the HRESIMS, which was assumed to be a trimeric flavonoid.¹⁷ The ¹H NMR spectrum (Table 1) displayed two isolated AB systems [δ_{H} 4.28, 4.38 and 4.18, 4.36 (each d, $J = 3.5$ Hz)] in the heterocyclic proton region, ascribed as a diagnostic feature of the C- and F-ring protons of A-type proanthocyanidins,¹⁵ indicating the presence of two doubly linked flavanyl units. The location of the interflavanyl linkage of **3** was established by analysis of the ¹H NMR spectrum and NOE correlations of the corresponding octamethyl ether (**3a**). The two upfield methoxy signals (δ_{H} 3.31 and 3.38), assignable to the methoxy groups at C-5 (A-ring) and C-5' (D-ring), and the NOE correlations of a methoxy signal at δ_{H} 3.38 (3H, s, MeO-5') with H-4' (δ_{H} 4.30,

F-ring) and a methoxy signal at δ_{H} 3.78 (3H, s, MeO-5'') with H-4'' (δ_{H} 2.60–3.11, I-ring) indicated, as for **2**, the presence of (4 \rightarrow 8, 2 \rightarrow O \rightarrow 7') and (4' \rightarrow 8'', 2' \rightarrow O \rightarrow 7'') interflavanil linkages in **3**. This was confirmed by the unsubstituted phloroglucinol A-ring carbons C-6 (δ_{C} 98.6) and C-8 (δ_{C} 96.8), C-6 (δ_{C} 96.9) of the D-ring, and C-6 (δ_{C} 98.6) of the G-ring in **3**. The ^1H NMR features of **3** were similar to those of **2**, but there were marked differences between **3** and **2** in the chemical shifts and splitting patterns of the aromatic protons of the E-ring; an AMX system [δ_{H} 6.83 (d, $J = 6.8$ Hz), 6.84 (dd, $J = 2.1, 6.8$ Hz), and 6.95 (dd, $J = 2.1$ Hz)] was observed in **3**, instead of an A_2B_2 system in **2**. Thus, **3** differed from **2** in the substitution pattern of the E-ring, substantiated by the ^{13}C NMR chemical shifts of C-4' (δ_{C} 146.6) and C-3' (δ_{C} 146.9) of the E-ring, as well as analysis of the HMBC spectrum (Figure 1). The absolute configuration of **3** was assigned as being identical to that of **2** on the basis of the Cotton effects and NOE correlations (Figure 2). Thus, the upper and middle flavanyl units of **3** were identified as *ent*-epiafzelechin and *ent*-epicatechin, respectively, and the lower flavanyl unit was characterized as *ent*-afzelechin, due to a positive Cotton effect around 272 nm ($[\Theta]_{272} +780$) in the ECD spectrum and the *trans* relationship ($J_{2,3} = 8.0$ Hz) between H-2 and H-3 of the I-ring. Consequently, the structure of **3** was assigned as *ent*-epiafzelechin-(2 α \rightarrow O \rightarrow 7,4 α \rightarrow 8)-*ent*-epicatechin-(2 α \rightarrow O \rightarrow 7,4 α \rightarrow 8)-*ent*-afzelechin.

The inhibitory effects of the isolated compounds (**1–6**) on AGE formation were examined in vitro according to a previously described procedure²⁰ using commercially available aminoguanidine, the first AGE inhibitor for the treatment of diabetic nephropathy,²¹ as a positive control. As shown in Table 2, all of the tested compounds exhibited considerable inhibition

Table 2. Inhibitory Effects of Compounds 1–6 from *S. ramalana* against AGE Formation^a

compound	IC ₅₀ ^b (μM)
1	32.1 \pm 0.5
2	39.8 \pm 3.6
3	17.4 \pm 0.5
4	34.7 \pm 2.8
5	33.5 \pm 2.0
6	14.1 \pm 1.6
aminoguanidine ^c	965.9 \pm 15.5

^aResults are expressed as means \pm SEM ($n = 3$). ^bIC₅₀ indicates the concentration (μM) at which the inhibition percentage of the AGE formation was 50%, and the values were determined by regression analysis. ^cPositive control.

of AGE formation, with IC₅₀ values ranging from 14.1 to 39.8 μM , compared with that of aminoguanidine (IC₅₀ = 965.9 \pm 15.5 μM). Of the tested compounds, compounds **3** and **6**, both of which have a catechol unit in the molecule, were the strongest inhibitors of AGE, with IC₅₀ values of 17.4 \pm 0.5 and 14.1 \pm 1.6 μM , respectively, and their activities were approximately twice those of the other isolates (**1**, **2**, **4**, and **5**) that do not contain a catechol unit, suggesting that the presence of catechol unit(s) in these A-type proanthocyanidins increases their AGE-inhibitory properties. We additionally found that epicatechin and epicatechin-3-O-gallate, commercially available compounds containing catechol units, notably inhibited AGE formation at IC₅₀ values of 13.6 \pm 0.3 and 15.1 \pm 0.2 μM , respectively. Because the presence of catechol

unit(s) in flavonoids is important to show substantial antioxidant activity, our result is consistent with previous reports that the AGE formation inhibitory activities of several flavonoids were closely associated with their antioxidant capacity.^{22,23}

Accumulation of AGE in retinal blood vessels plays an important role in the onset and development of diabetic retinopathy.²⁴ Experimental studies have shown that specific inhibitors of AGE formation effectively reduce retinal microvascular lesions in diabetic animal models.^{25,26} Recently, it has been reported that the retinal vessels of the hyperglycemic adult zebrafish increase in diameter (compared to normal animals).²⁷ Thus, to evaluate the effects of compounds **1–6** on retinopathy, an in vivo diabetic zebrafish model was used. The change in the extent of hyaloid-retinal vessel dilation was assessed using zebrafish *flk:EGFP* transgenic embryos held under high-glucose (30 mM) conditions. Dilation was reduced by treatment with compounds **1–6**; compound **3**, which contains a catechol unit, was most effective in this regard. Vessels treated with **3** were significantly thinner than were those of the control group (Figure 3B–D), and no cytotoxicity was evident at the concentrations tested. Quantitative analysis revealed that **3** reduced the diameters of HG-induced hyaloid-retinal vessels by 157.7% and 164.1% when used at 10 and 20 μM , respectively, compared to the HG-treated control group (Figure 3F). Compound **6** also reduced HG-induced dilation of hyaloid-retinal vessels, albeit to a lesser extent (104.0% inhibition at 20 μM) than did **3** (see Supporting Information). Our results suggest that compound **3** inhibits development of experimental retinopathy at early larval stages.

Proanthocyanidins represent a unique class of oligomeric and polymeric end-products of the flavonoid biosynthetic pathway. The materials are widespread throughout the plant kingdom and exhibit a number of biological properties, including antioxidant, antibacterial, antiviral, anticarcinogenic, anti-inflammatory, and antiallergic activities.^{28–30} Our current study of novel AGE inhibitors from *S. ramalana* resulted in isolation of three new (**1–3**) and three known dimeric A-type proanthocyanidins (**4–6**). This is the first report of the occurrence of A-type proanthocyanidins in the genus *Spenceria*. Compounds **1–6** notably inhibited AGE formation with IC₅₀ values ranging from 14.1 to 39.8 μM . Compound **3** also significantly reduced dilation of HG-induced hyaloid retinal vessels in a diabetic zebrafish model. Our results suggest that *S. ramalana* and active components thereof may be beneficial to treat and prevent diabetic vascular complications and other related diseases.

EXPERIMENTAL SECTION

General Experimental Procedures. Optical rotations were measured on a JASCO P-2000 digital polarimeter. ECD spectra were measured on a JASCO J-715 spectrometer. IR spectra were recorded on a JASCO 100 IR spectrometer. All 1D (^1H and ^{13}C) and 2D (HMQC, HMBC, and NOESY) NMR spectra were obtained using a Bruker Avance 500 NMR spectrometer with TMS as an internal standard. HRESIMS were recorded on a Shimadzu LCMS-IT-TOF spectrometer. Column chromatography was performed using silica gel (70–230 mesh and 230–400 mesh, Merck) and Sephadex LH-20 (Amersham Pharmacia Biotech). Thin-layer chromatography (TLC) was performed on precoated silica gel 60 F₂₅₄ (0.25 mm, Merck) and RP-18 F_{254s} plates (0.25 mm, Merck). Spots were detected by UV light (254 nm) and spraying with 10% H₂SO₄ followed by heating.

Plant Material. The whole plant of *S. ramalana* was collected from an alpine meadow in Lijiang, China, in September 2008, and identified

2a: white powder; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ_{H} 2.58–3.10 (2H, m, H-4''), 3.33 (3H, s, MeO-5), 3.40 (3H, s, MeO-5'), 3.70 (3H, s, MeO-5''), 3.73 (3H, s, MeO-7), 3.78 (3H, s, MeO-14''), 3.81 (3H, s, MeO-14'), 3.83 (3H, s, MeO-14), 4.04 (1H, m, H-3''), 4.12 (1H, d, $J = 3.5$ Hz, H-3'), 4.25 (1H, d, $J = 3.5$ Hz, H-3), 4.30 (1H, d, $J = 3.5$ Hz, H-4 or H-4'), 4.32 (1H, d, $J = 3.5$ Hz, H-4 or H-4'), 4.70 (1H, d, $J = 8.0$ Hz, H-2''), 5.98 (1H, d, $J = 2.2$ Hz, H-6''), 6.08 (1H, d, $J = 2.2$ Hz, H-6), 6.18 (1H, d, $J = 2.2$ Hz, H-6'), 6.20 (1H, d, $J = 2.2$ Hz, H-8), 6.92–7.70 (12H, aromatic protons in rings B, E, and H); ESIMS m/z 911.2 $[\text{M} - \text{H}]^-$.

3a: white powder; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ_{H} 2.60–3.11 (2H, m, H-4''), 3.31 (3H, s, MeO-5), 3.38 (3H, s, MeO-5'), 3.68 (3H, s, MeO-13'), 3.74 (3H, s, MeO-14'), 3.78 (3H, s, MeO-5''), 3.83 (3H, s, MeO-7), 3.87 (3H, s, MeO-14''), 3.90 (3H, s, MeO-14), 4.03 (1H, m, H-3''), 4.14 (1H, d, $J = 3.5$ Hz, H-3'), 4.26 (1H, d, $J = 3.5$ Hz, H-3), 4.30 (1H, d, $J = 3.5$ Hz, H-4'), 4.34 (1H, d, $J = 3.5$ Hz, H-4), 4.70 (1H, d, $J = 8.0$ Hz, H-2''), 5.96 (1H, d, $J = 2.2$ Hz, H-6''), 6.07 (1H, d, $J = 2.2$ Hz, H-6), 6.19 (1H, d, $J = 2.2$ Hz, H-6'), 6.20 (1H, d, $J = 2.2$ Hz, H-8), 6.90–7.72 (11H, aromatic protons in rings B, E, and H); ESIMS m/z 941.3 $[\text{M} - \text{H}]^-$.

Acid Hydrolysis of 1. Compound **1** (5 mg) in 10% HCl–dioxane (1:1, 1 mL) was heated at 80 °C for 3 h in a water bath. The mixture was neutralized with Ag_2CO_3 , filtered, and extracted with EtOAc (20 mL). The EtOAc layer was evaporated, and the residue subjected to reversed-phase HPLC [Agilent 1200 system; YMC-pack Pro C_{18} column (250 × 10 mm, i.d.); MeOH– H_2O (30:70, v/v); UV detection, 270 nm; flow rate, 3.0 mL/min] to give *ent*-epiafzelechin-(2 α →O→7,4 α →8)-*ent*-afzelechin (**4**, 2 mg), identified by comparing spectroscopic data with literature data. The aqueous layer was evaporated, and the residue was treated with L-cysteine methyl ester hydrochloride (2 mg) in pyridine (0.5 mL) at 60 °C for 1 h. After the reaction was completed, the solution was treated with Ac_2O (3 mL) at 60 °C for 1 h. Authentic samples were prepared by the same procedure. The acetate derivatives were subjected to gas chromatography (GC) analysis. GC conditions: GC-2010 (Shimadzu) instrument; detector, FID; column, TC-1 capillary column (0.25 mm × 30 m; GL Science, Inc.); column temperature, 230 °C; programmed increase, 38 °C/min; carrier gas, N_2 (1 mL/min); injection and detector temperature, 270 °C. The sugar derivative thus obtained showed a retention time of 21.30 min, identical to that of authentic D-glucose.

Determination of AGE Formation. According to a well-established method, the reaction mixture [bovine serum albumin (10 mg/mL, Sigma, St. Louis, MO, USA; 700 μL) in 50 mM phosphate buffer (pH 7.4) with 0.02% sodium azide] was added to 0.2 M fructose and glucose (100 μL). In screw cap tubes (1.5 mL), the reaction mixture was mixed with 200 μL of serially diluted compounds and aminoguanidine (Sigma). After incubating at 37 °C for 7 days, the fluorescent reaction products (200 μL) were transferred to 96-well plates and assayed on a spectrofluorometric detector (Bio-Tek, Synergy HT, USA; excitation wavelength, 350 nm; emission wavelength, 450 nm). The AGE assay was performed in triplicate. The concentration of each test sample giving 50% inhibition of the activity (IC_{50}) was estimated from the least-squares regression line of the logarithmic concentration plotted against remaining activity.

Measurement of Vessel Dilation in Larval Zebrafish. Adult zebrafish were maintained under standard conditions at 28.5 °C under a 14 h light/10 h dark cycle. Embryos were obtained from crosses between *flk*:EGFP Tg (transgenic) fish and raised in egg water (sea salt, 0.06 g/L). One-day *flk*:EGFP Tg embryos were placed into 24-well plates (five embryos per well) and maintained in 2 mL volumes of egg water with 30 mM glucose. HG-induced embryos were treated with 10 or 20 μM of compounds from 1 day postfertilization (dpf) to 6 dpf. At 6 dpf, HG-induced embryos were fixed with 4% (v/v) paraformaldehyde, and each lens containing hyaloid retinal vessels was isolated and aligned so that the optic disc (OD) was facing upward. Fluorescence images were obtained using an Olympus SZX16 stereomicroscope. The diameters of hyaloid vessels were measured in 3–4 main branches of the OD, to the first sub-branch, using the Image J software. All experiments were performed in triplicate.

Statistical Analysis. Hyaloid vessel diameter was used to calculate the percentage inhibition of compound **3** in HG-treated embryos according to the formula

$$\text{percentage inhibition (\%)} = [1 - (T_n - C_{av}) / (HG_{av} - C_{av})] \times 100$$

where C_{av} = average of hyaloid-vessel diameter (SI) in the control embryos, HG_{av} = average of hyaloid-vessel diameter (SI) in the HG-treated embryos, and T_n = hyaloid-vessel diameter (SI) of the HG-treated embryos with compound **3**. The results are expressed as means \pm standard error of the mean (SEM) from three independent experiments. Statistical significance was assessed using one-way analysis of variance (ANOVA) and Dunnett's multiple comparison tests with the GraphPad 5.0 Prism software (GraphPad, San Diego, CA, USA).

■ ASSOCIATED CONTENT

📄 Supporting Information

$^1\text{H NMR}$, $^{13}\text{C NMR}$, NOESY, and mass spectra for the new compounds **1–3** and zebrafish data of compound **6**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: +82-42-868-9465. Fax: +82-42-868-9471. E-mail: jskim@kiom.re.kr

Author Contributions

[†]I.-S. Lee and S. Y. Yu contributed equally to this work.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by a grant (K12040, K13040) from the Korea Institute of Oriental Medicine. The NMR and MS experiments were performed by the Korea Basic Science Institute (KBSI). The authors thank Prof. C.-H. Kim (Chungnam National University, Daejeon, Republic of Korea) for providing zebrafish lines and for technical support.

■ REFERENCES

- (1) Wei, M.; Gaskill, S. P.; Hanffner, S. M.; Stern, M. P. *Diabetes Care* **1998**, *21*, 1167–1172.
- (2) Laakso, M. *Diabetes* **1999**, *48*, 937–942.
- (3) Nishikawa, T.; Edelstein, D.; Du, X. L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M. A.; Beebe, D.; Oates, P. J.; Hammes, H. P.; Giardino, I.; Brownlee, M. *Nature* **2000**, *404*, 787–790.
- (4) Brownlee, M. *Nature* **2001**, *414*, 813–820.
- (5) Takenaka, K.; Yamagishi, S.; Matsui, T.; Nakamura, K.; Imaizumi, T. *Curr. Neurovasc. Res.* **2006**, *3*, 73–77.
- (6) Li, C.; Ikeda, H.; Ohba, H. In Wu, Z. Y.; Raven, P. H.; Hong, D. Y., Eds. *Flora of China*, Vol. 9; Science Press: Beijing, and Missouri Botanical Garden Press: St. Louis, 2003; p 384.
- (7) Bilia, A. R.; Morelli, I.; Hamburger, M.; Hostettmann, K. *Phytochemistry* **1996**, *43*, 887–892.
- (8) Rawat, M. S. M.; Prasad, D.; Joshi, R. K.; Pant, G. *Phytochemistry* **1999**, *50*, 321–324.
- (9) Prasad, D. *Fitoterapia* **2000**, *71*, 245–253.
- (10) Mabry, T. J.; Markham, K. R.; Thomas, M. B. *The Systematic Identification of Flavonoids*; Springer: New York, 1970; p 41.
- (11) Jacques, D.; Haslam, E.; Bedford, G. R.; Greatbanks, D. J. *Chem. Soc., Perkin Trans. 1* **1974**, 2663–2671.
- (12) Lou, H.; Yamazaki, Y.; Sasaki, T.; Uchida, M.; Tanaka, H.; Oka, S. *Phytochemistry* **1999**, *51*, 297–308.

- (13) Kolodziej, H.; Sakar, M. K.; Burger, J. F. W.; Engelshowe, R.; Ferreira, D. *Phytochemistry* **1991**, *30*, 2041–2047.
- (14) Botha, J. J.; Young, D. A.; Ferreira, D.; Roux, D. G. *J. Chem. Soc., Perkin Trans. 1* **1981**, 1213–1219.
- (15) Hikino, H.; Shimoyama, N.; Kasahara, Y.; Takahashi, M.; Konno, C. *Heterocycles* **1982**, *19*, 1381–1384.
- (16) Korver, O.; Wilkins, C. K. *Tetrahedron* **1971**, *27*, 5459–5465.
- (17) Balde, A. M.; De Bruyne, T.; Pieters, L.; Kolodziej, H.; Berghe, D. V.; Claeys, M.; Vlietinck, A. *Phytochemistry* **1995**, *38*, 719–723.
- (18) Morimoto, S.; Nonaka, G. I.; Nishioka, I. *Chem. Pharm. Bull.* **1987**, *35*, 4717–4729.
- (19) Calzada, F.; Cedillo-Rivera, R.; Bye, R.; Mata, R. *Planta Med.* **2001**, *67*, 677–680.
- (20) Jang, D. S.; Yoo, N. H.; Kim, N. H.; Lee, Y. M.; Kim, C. S.; Kim, J.; Kim, J. H.; Kim, J. S. *Biol. Pharm. Bull.* **2010**, *33*, 329–333.
- (21) Brownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A. *Science* **1986**, *232*, 1629–1632.
- (22) Morimitsu, Y.; Yoshida, K.; Esaki, S.; Hirota, A. *Biosci. Biotechnol. Biochem.* **1995**, *59*, 2018–2021.
- (23) Lou, H.; Yuan, H.; Yamazaki, Y.; Sasaki, T.; Oka, S. *Planta Med.* **2001**, *67*, 345–349.
- (24) Stitt, A. W.; Li, Y. M.; Gardiner, T. A.; Bucala, R.; Archer, D. B.; Vlassara, H. *Am. J. Pathol.* **1997**, *150*, 523–531.
- (25) Stitt, A.; Gardiner, T. A.; Alderson, N. L.; Canning, P.; Frizzell, N.; Duffy, N.; Boyle, C.; Januszewski, A. S.; Chachich, M.; Baynes, J. W.; Thorpe, S. R. *Diabetes* **2002**, *51*, 2826–2832.
- (26) Gardiner, T. A.; Anderson, H. R.; Stitt, A. W. *J. Pathol.* **2003**, *201*, 328–333.
- (27) Alvarez, Y.; Chen, K.; Reynolds, A. L.; Waghorne, N.; O'Connor, J. J.; Kennedy, B. N. *Dis. Model. Mech.* **2010**, *3*, 236–245.
- (28) Bagchi, D.; Garg, A.; Krohn, R. L.; Bagchi, M.; Tran, M. X.; Stohs, S. J. *Res. Commun. Mol. Pathol. Pharmacol.* **1997**, *95*, 179–189.
- (29) Bagchi, M.; Bagchi, D. J.; Balmoori, J.; Stohs, S. J. *Gen. Pharmacol.* **1998**, *30*, 771–776.
- (30) Shahat, A. A.; Cos, P.; De Bruyne, T.; Apers, S.; Hammouda, F. M.; Ismail, S. I.; Azzam, S.; Claeys, M.; Goovaerts, E.; Pieters, L.; Vanden Berghe, D.; Vlietinck, A. J. *Planta Med.* **2002**, *68*, 539–541.